Expert Interview
Discussing Regenexbio's Phase I/II trial results for RGX-202 gene therapy for patients with Duchenne muscular dystrophy (DMD)
Ticker(s): RGNXInstitution: Advocate Medical Group
- Currently manages around 40 patients with Duchenne muscular dystrophy.
- Extremely familiar with this recent readout and publicly available data on this gene therapy asset as well the differentiation from Elevidys in terms of mechanism, microdystrophin characteristics, efficacy, vector used and safety.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
